Lesia K Dropulic MD
Transplant/Immunocompromised States
Chief, Clinical Trials Program Vaccine Research Center, National Institute of Allergy and Infectious Diseases
Join to View Full Profile
9000 Rockville PikeBG T40 Rm 150Bethesda, MD 20892
Phone+1 301-412-2708
Dr. Dropulic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Lesia Dropulic, MD, specializes in infectious diseases with a focus on transplant and immunocompromised states, having completed her fellowship at Johns Hopkins University. Currently located in Bethesda, MD, she serves as the Chief of the Clinical Trials Program at the Vaccine Research Center within the National Institute of Allergy and Infectious Diseases. Her professional experience includes roles at the NIH Clinical Center and Johns Hopkins University School of Medicine. Dr. Dropulic's research encompasses infectious diseases, clinical trials, and vaccines, with several publications in distinguished journals like Science Translational Medicine and The Lancet. She actively leads clinical trials evaluating investigational vaccines and monoclonal antibodies against influenza, HIV, and Nipah virus.
Education & Training
Johns Hopkins UniversityFellowship, Infectious Disease, 1992 - 1997
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1989 - 1992
Wayne State University School of MedicineClass of 1989
Certifications & Licensure
MD State Medical License 1992 - 2026
Clinical Trials
- The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise Start of enrollment: 2009 Oct 01
- Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection Start of enrollment: 2013 Sep 26
- Challenge Infection of Healthy Adult Volunteers With RSV A2 Start of enrollment: 2018 Feb 20
Publications & Presentations
PubMed
- Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses.Alexandra A Abu-Shmais, Gray Freeman, Adrian Creanga, Matthew J Vukovich, Tek Malla
Nature Microbiology. 2025-11-01 - 2 citationsSafety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults.Richard L Wu, Katherine V Houser, Martin R Gaudinski, Alicia T Widge, Seemal F Awan
The Lancet. HIV. 2025-07-01 - 2 citationsEarly influenza virus exposure shapes the B cell response to influenza vaccination in individuals 50 years later.Abby Spangler, Geoffrey D Shimberg, Grace E Mantus, Rory Malek, Lauren Y Cominsky
Immunity. 2025-03-11
Other Languages
- Ukrainian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
